We show that there is a reduction in adiponectin receptor levels in mouse and human pancreatic cancer tumors and cell lines relative to normal pancreas tissue and report that supplementation with adiponectin or the adiponectin receptor agonist, AdipoRon, suppresses leptin-induced STAT3 signaling in vitro and reduces PDAC tumor growth in vivo. This evidence concerns the gene ADIPOQ and neoplasm.